Startseite>>Signaling Pathways>> Others>>SPRi 3

SPRi 3 (Synonyms: SPRi3)

Katalog-Nr.GC50516

SPRi 3 (SPRi3) ist ein potenter Hemmer der Sepiapterinreduktase (SPR).

Products are for research use only. Not for human use. We do not sell to patients.

SPRi 3 Chemische Struktur

Cas No.: 1292285-54-1

Größe Preis Lagerbestand Menge
10 mg
175,00 $
Auf Lager
50 mg
595,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Potent sepiapterin reductase (SPR) inhibitor (IC50 = 53 - 74 nM for human SPR). Inhibits BH4 synthesis pathway and attenuates proliferation in naive CD4+ T cells. Suppresses proliferation of human effector CD4+ T cells following stimulation. Reduces SPR activity in mouse primary cultures of sensory neurons (IC50 = 450 nM). Ameliorates colitis, suppressing the intestinal infiltration of T cells and other immune cells in vivo. Also reduces immune-cell infiltration into mouse lungs. Reduces neuropathic and inflammatory pain in mouse models.

Haruki et al (2016) Tetrahydrobiopterin biosynthesis as a potential target of the kynurenine pathway metabolite xanthurenic acid. J.Biol.Chem. 291 652 PMID:26565027 |Latremoliere et al (2015) Reduction of neuropathic and inflammatory pain through inhibition of the tetrahydrobiopterin pathway. Neuron 86 1393 PMID:26087165 |Cronin et al (2018) The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature 563 564 PMID:30405245

Bewertungen

Review for SPRi 3

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SPRi 3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.